questionsmedicales.fr
Facteurs biologiques
Pigments biologiques
Pigments rétiniens
Pigments rétiniens : Questions médicales fréquentes
Termes MeSH sélectionnés :
Vascular Endothelial Growth Factor A
Diagnostic
5
Pigments rétiniens
Examen ophtalmologique
Électrorétinogramme
Imagerie par résonance magnétique
Antécédents familiaux
Maladies rétiniennes
Perte de vision
Champ visuel
Tests génétiques
Mutations
Symptômes
5
Dégénérescence rétinienne
Vision nocturne
Photophobie
Sensibilité à la lumière
Perte de vision centrale
Champ visuel
Halos
Anomalies rétiniennes
Troubles de la couleur
Perception des couleurs
Prévention
5
Prévention
Mode de vie sain
Exposition au soleil
Lunettes de soleil
Antioxydants
Dommages oxydatifs
Examens oculaires
Anomalies rétiniennes
Tabagisme
Santé rétinienne
Traitements
5
Thérapies géniques
Suppléments nutritionnels
Thérapie génique
Dégénérescence pigmentaire
Vitamine A
Maladies rétiniennes
Aides visuelles
Qualité de vie
Essais cliniques
Traitements innovants
Complications
5
Troubles psychologiques
Dépression
Qualité de vie
Complications visuelles
Complications
Gestion des symptômes
Complications rapides
Attention médicale
Facteurs de risque
5
Maladies génétiques
Rétinite pigmentaire
Diabète
Complications rétiniennes
Exposition professionnelle
Lumière intense
Sexe
Conditions rétiniennes
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Pigments rétiniens : Questions médicales les plus fréquentes",
"headline": "Pigments rétiniens : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Pigments rétiniens : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-07-26",
"dateModified": "2026-01-17",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Pigments rétiniens"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Pigments biologiques",
"url": "https://questionsmedicales.fr/mesh/D010860",
"about": {
"@type": "MedicalCondition",
"name": "Pigments biologiques",
"code": {
"@type": "MedicalCode",
"code": "D010860",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.767"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Opsines",
"alternateName": "Opsins",
"url": "https://questionsmedicales.fr/mesh/D055355",
"about": {
"@type": "MedicalCondition",
"name": "Opsines",
"code": {
"@type": "MedicalCode",
"code": "D055355",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.767.930.750"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Opsines des cônes",
"alternateName": "Cone Opsins",
"url": "https://questionsmedicales.fr/mesh/D055358",
"about": {
"@type": "MedicalCondition",
"name": "Opsines des cônes",
"code": {
"@type": "MedicalCode",
"code": "D055358",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.767.930.750.249"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Opsines des bâtonnets",
"alternateName": "Rod Opsins",
"url": "https://questionsmedicales.fr/mesh/D017299",
"about": {
"@type": "MedicalCondition",
"name": "Opsines des bâtonnets",
"code": {
"@type": "MedicalCode",
"code": "D017299",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.767.930.750.500"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Rhodopsine",
"alternateName": "Rhodopsin",
"url": "https://questionsmedicales.fr/mesh/D012243",
"about": {
"@type": "MedicalCondition",
"name": "Rhodopsine",
"code": {
"@type": "MedicalCode",
"code": "D012243",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.767.930.750.500.500"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Rhodopsine",
"alternateName": "Rhodopsin",
"url": "https://questionsmedicales.fr/mesh/D012243",
"about": {
"@type": "MedicalCondition",
"name": "Rhodopsine",
"code": {
"@type": "MedicalCode",
"code": "D012243",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D23.767.930.750.500.500"
}
}
}
]
}
],
"about": {
"@type": "MedicalCondition",
"name": "Pigments rétiniens",
"alternateName": "Retinal Pigments",
"code": {
"@type": "MedicalCode",
"code": "D012168",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Carol L Shields",
"url": "https://questionsmedicales.fr/author/Carol%20L%20Shields",
"affiliation": {
"@type": "Organization",
"name": "Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania, USA."
}
},
{
"@type": "Person",
"name": "N L Sheremet",
"url": "https://questionsmedicales.fr/author/N%20L%20Sheremet",
"affiliation": {
"@type": "Organization",
"name": "Research Institute of Eye Diseases, 11A Rossolimo St., Moscow, Russian Federation, 119021."
}
},
{
"@type": "Person",
"name": "A A Mikaelyan",
"url": "https://questionsmedicales.fr/author/A%20A%20Mikaelyan",
"affiliation": {
"@type": "Organization",
"name": "Research Institute of Eye Diseases, 11A Rossolimo St., Moscow, Russian Federation, 119021."
}
},
{
"@type": "Person",
"name": "S L Kiselev",
"url": "https://questionsmedicales.fr/author/S%20L%20Kiselev",
"affiliation": {
"@type": "Organization",
"name": "Vavilov Institute of General Genetics, 3 Gubkina St., Moscow, Russian Federation, 119333."
}
},
{
"@type": "Person",
"name": "Maria Vittoria Cicinelli",
"url": "https://questionsmedicales.fr/author/Maria%20Vittoria%20Cicinelli",
"affiliation": {
"@type": "Organization",
"name": ""
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "Vascular endothelial growth factor receptor 1 gene (",
"datePublished": "2023-05-12",
"url": "https://questionsmedicales.fr/article/37178326",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.18632/aging.204722"
}
},
{
"@type": "ScholarlyArticle",
"name": "Anti-vascular endothelial growth factor for neovascular glaucoma.",
"datePublished": "2023-04-03",
"url": "https://questionsmedicales.fr/article/37010901",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/14651858.CD007920.pub4"
}
},
{
"@type": "ScholarlyArticle",
"name": "Anti-vascular endothelial growth factor for proliferative diabetic retinopathy.",
"datePublished": "2023-03-20",
"url": "https://questionsmedicales.fr/article/36939655",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1002/14651858.CD008721.pub3"
}
},
{
"@type": "ScholarlyArticle",
"name": "Vascular endothelial growth factor (VEGF) delivery approaches in regenerative medicine.",
"datePublished": "2023-08-08",
"url": "https://questionsmedicales.fr/article/37562236",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1016/j.biopha.2023.115301"
}
},
{
"@type": "ScholarlyArticle",
"name": "Mandibular condylar hyperplasia and its correlation with vascular endothelial growth factor.",
"datePublished": "2023-05-18",
"url": "https://questionsmedicales.fr/article/37133441",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/joor.13487"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Facteurs biologiques",
"item": "https://questionsmedicales.fr/mesh/D001685"
},
{
"@type": "ListItem",
"position": 3,
"name": "Pigments biologiques",
"item": "https://questionsmedicales.fr/mesh/D010860"
},
{
"@type": "ListItem",
"position": 4,
"name": "Pigments rétiniens",
"item": "https://questionsmedicales.fr/mesh/D012168"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Pigments rétiniens - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Pigments rétiniens",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2026-02-06",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Pigments rétiniens",
"description": "Comment diagnostiquer une anomalie des pigments rétiniens ?\nQuels tests sont utilisés pour évaluer les pigments rétiniens ?\nLes antécédents familiaux influencent-ils le diagnostic ?\nQuels signes cliniques indiquent un problème de pigments rétiniens ?\nLes tests génétiques sont-ils utiles pour le diagnostic ?",
"url": "https://questionsmedicales.fr/mesh/D012168?mesh_terms=Vascular+Endothelial+Growth+Factor+A#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Pigments rétiniens",
"description": "Quels sont les symptômes d'une dégénérescence des pigments rétiniens ?\nLa photophobie est-elle un symptôme courant ?\nComment se manifeste la perte de vision centrale ?\nLes halos autour des lumières sont-ils un symptôme ?\nLes troubles de la couleur sont-ils liés aux pigments rétiniens ?",
"url": "https://questionsmedicales.fr/mesh/D012168?mesh_terms=Vascular+Endothelial+Growth+Factor+A#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Pigments rétiniens",
"description": "Peut-on prévenir les troubles des pigments rétiniens ?\nL'exposition au soleil affecte-t-elle les pigments rétiniens ?\nUne alimentation riche en antioxydants est-elle bénéfique ?\nLes examens oculaires réguliers sont-ils importants ?\nLe tabagisme influence-t-il la santé rétinienne ?",
"url": "https://questionsmedicales.fr/mesh/D012168?mesh_terms=Vascular+Endothelial+Growth+Factor+A#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Pigments rétiniens",
"description": "Quels traitements existent pour les troubles des pigments rétiniens ?\nLa thérapie génique est-elle efficace ?\nLes suppléments de vitamine A sont-ils recommandés ?\nLes aides visuelles peuvent-elles aider les patients ?\nY a-t-il des traitements expérimentaux disponibles ?",
"url": "https://questionsmedicales.fr/mesh/D012168?mesh_terms=Vascular+Endothelial+Growth+Factor+A#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Pigments rétiniens",
"description": "Quelles complications peuvent survenir avec des troubles des pigments rétiniens ?\nLes troubles psychologiques sont-ils possibles ?\nLes complications peuvent-elles affecter la qualité de vie ?\nLes complications sont-elles réversibles ?\nLes complications peuvent-elles survenir rapidement ?",
"url": "https://questionsmedicales.fr/mesh/D012168?mesh_terms=Vascular+Endothelial+Growth+Factor+A#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Pigments rétiniens",
"description": "Quels sont les principaux facteurs de risque ?\nLes maladies génétiques augmentent-elles le risque ?\nLe diabète est-il un facteur de risque ?\nL'exposition professionnelle à la lumière est-elle un risque ?\nLe sexe influence-t-il le risque de troubles rétiniens ?",
"url": "https://questionsmedicales.fr/mesh/D012168?mesh_terms=Vascular+Endothelial+Growth+Factor+A#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une anomalie des pigments rétiniens ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Un examen ophtalmologique complet, incluant l'angiographie et l'électrorétinogramme, est nécessaire."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer les pigments rétiniens ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests incluent l'électrorétinogramme et l'imagerie par résonance magnétique."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux influencent-ils le diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de maladies rétiniennes peuvent orienter le diagnostic."
}
},
{
"@type": "Question",
"name": "Quels signes cliniques indiquent un problème de pigments rétiniens ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des signes comme la perte de vision nocturne ou des taches dans le champ visuel peuvent indiquer un problème."
}
},
{
"@type": "Question",
"name": "Les tests génétiques sont-ils utiles pour le diagnostic ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les tests génétiques peuvent identifier des mutations liées aux troubles des pigments rétiniens."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une dégénérescence des pigments rétiniens ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent la vision nocturne altérée, la perte de vision périphérique et des taches visuelles."
}
},
{
"@type": "Question",
"name": "La photophobie est-elle un symptôme courant ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la photophobie, ou sensibilité à la lumière, peut être un symptôme associé aux troubles rétiniens."
}
},
{
"@type": "Question",
"name": "Comment se manifeste la perte de vision centrale ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "La perte de vision centrale se manifeste par une vision floue ou des zones sombres au centre du champ visuel."
}
},
{
"@type": "Question",
"name": "Les halos autour des lumières sont-ils un symptôme ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les halos autour des lumières peuvent indiquer une anomalie des pigments rétiniens."
}
},
{
"@type": "Question",
"name": "Les troubles de la couleur sont-ils liés aux pigments rétiniens ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles de la perception des couleurs peuvent survenir avec des anomalies des pigments rétiniens."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les troubles des pigments rétiniens ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "La prévention est limitée, mais un mode de vie sain et des examens réguliers peuvent aider."
}
},
{
"@type": "Question",
"name": "L'exposition au soleil affecte-t-elle les pigments rétiniens ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une exposition excessive au soleil peut endommager les pigments rétiniens, d'où l'importance des lunettes de soleil."
}
},
{
"@type": "Question",
"name": "Une alimentation riche en antioxydants est-elle bénéfique ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation riche en antioxydants peut protéger la rétine des dommages oxydatifs."
}
},
{
"@type": "Question",
"name": "Les examens oculaires réguliers sont-ils importants ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des examens réguliers permettent de détecter précocement les anomalies rétiniennes."
}
},
{
"@type": "Question",
"name": "Le tabagisme influence-t-il la santé rétinienne ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le tabagisme est un facteur de risque pour plusieurs maladies rétiniennes, y compris les troubles des pigments."
}
},
{
"@type": "Question",
"name": "Quels traitements existent pour les troubles des pigments rétiniens ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les traitements incluent des thérapies géniques, des suppléments nutritionnels et des aides visuelles."
}
},
{
"@type": "Question",
"name": "La thérapie génique est-elle efficace ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la thérapie génique peut améliorer la fonction rétinienne dans certains cas de dégénérescence pigmentaire."
}
},
{
"@type": "Question",
"name": "Les suppléments de vitamine A sont-ils recommandés ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des études suggèrent que la vitamine A peut ralentir la progression de certaines maladies rétiniennes."
}
},
{
"@type": "Question",
"name": "Les aides visuelles peuvent-elles aider les patients ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les aides visuelles comme les lunettes spéciales peuvent améliorer la qualité de vie des patients."
}
},
{
"@type": "Question",
"name": "Y a-t-il des traitements expérimentaux disponibles ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des essais cliniques sur des traitements innovants sont en cours pour les troubles rétiniens."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec des troubles des pigments rétiniens ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les complications incluent la cécité, la déformation du champ visuel et des troubles de la perception des couleurs."
}
},
{
"@type": "Question",
"name": "Les troubles psychologiques sont-ils possibles ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la perte de vision peut entraîner des troubles psychologiques comme la dépression ou l'anxiété."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles affecter la qualité de vie ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les complications visuelles peuvent significativement réduire la qualité de vie des patients."
}
},
{
"@type": "Question",
"name": "Les complications sont-elles réversibles ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certaines complications peuvent être gérées, mais beaucoup ne sont pas réversibles."
}
},
{
"@type": "Question",
"name": "Les complications peuvent-elles survenir rapidement ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines complications peuvent se développer rapidement, nécessitant une attention médicale immédiate."
}
},
{
"@type": "Question",
"name": "Quels sont les principaux facteurs de risque ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent l'âge, les antécédents familiaux, et l'exposition à la lumière intense."
}
},
{
"@type": "Question",
"name": "Les maladies génétiques augmentent-elles le risque ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines maladies génétiques comme la rétinite pigmentaire augmentent le risque de troubles rétiniens."
}
},
{
"@type": "Question",
"name": "Le diabète est-il un facteur de risque ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le diabète peut entraîner des complications rétiniennes, augmentant le risque de troubles des pigments."
}
},
{
"@type": "Question",
"name": "L'exposition professionnelle à la lumière est-elle un risque ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les travailleurs exposés à une lumière intense peuvent avoir un risque accru de troubles rétiniens."
}
},
{
"@type": "Question",
"name": "Le sexe influence-t-il le risque de troubles rétiniens ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, certaines conditions rétiniennes sont plus fréquentes chez les hommes que chez les femmes."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 17/01/2026
Contenu vérifié selon les dernières recommandations médicales
3 publications dans cette catégorie
Affiliations :
Ocular Oncology Service, Wills Eye Hospital, Thomas Jefferson University, Philadelphia, Pennsylvania, USA.
Publications dans "Pigments rétiniens" :
3 publications dans cette catégorie
Affiliations :
Research Institute of Eye Diseases, 11A Rossolimo St., Moscow, Russian Federation, 119021.
Publications dans "Pigments rétiniens" :
3 publications dans cette catégorie
Affiliations :
Research Institute of Eye Diseases, 11A Rossolimo St., Moscow, Russian Federation, 119021.
Publications dans "Pigments rétiniens" :
3 publications dans cette catégorie
Affiliations :
Vavilov Institute of General Genetics, 3 Gubkina St., Moscow, Russian Federation, 119333.
Publications dans "Pigments rétiniens" :
3 publications dans cette catégorie
Publications dans "Pigments rétiniens" :
2 publications dans cette catégorie
Affiliations :
LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear and Throat Hospital, New York, New York.
Vitreous Retina Macula Consultants of New York, New York, New York.
Department of Ophthalmology, Rabin Medical Center, Petach-Tikva, Israel.
Publications dans "Pigments rétiniens" :
2 publications dans cette catégorie
Affiliations :
LuEsther T. Mertz Retinal Research Center, Manhattan Eye, Ear and Throat Hospital, New York, New York.
Vitreous Retina Macula Consultants of New York, New York, New York.
Department of Ophthalmology, New York University School of Medicine, New York, New York.
Publications dans "Pigments rétiniens" :
2 publications dans cette catégorie
Affiliations :
Department of Ophthalmology, Tokyo Medical University, Ibaraki Medical Center, Inashiki, Japan. m-miura@tokyo-med.ac.jp.
Department of Ophthalmology, Tokyo Medical University, Tokyo, Japan. m-miura@tokyo-med.ac.jp.
Publications dans "Pigments rétiniens" :
2 publications dans cette catégorie
Affiliations :
Computational Optics Group, University of Tsukuba, Tsukuba, Japan.
Publications dans "Pigments rétiniens" :
2 publications dans cette catégorie
Affiliations :
Computational Optics Group, University of Tsukuba, Tsukuba, Japan.
Publications dans "Pigments rétiniens" :
2 publications dans cette catégorie
Affiliations :
Computational Optics Group, University of Tsukuba, Tsukuba, Japan.
Publications dans "Pigments rétiniens" :
2 publications dans cette catégorie
Affiliations :
Topcon Corporation, Tokyo, Japan.
Publications dans "Pigments rétiniens" :
2 publications dans cette catégorie
Affiliations :
Topcon Corporation, Tokyo, Japan.
Publications dans "Pigments rétiniens" :
2 publications dans cette catégorie
Affiliations :
Department of Ophthalmology, Tokyo Medical University, Ibaraki Medical Center, Inashiki, Japan.
Department of Ophthalmology, Tokyo Medical University, Tokyo, Japan.
Publications dans "Pigments rétiniens" :
2 publications dans cette catégorie
Affiliations :
Eye Center of the Second Hospital of Jilin University, Changchun, Jilin, China.
Publications dans "Pigments rétiniens" :
2 publications dans cette catégorie
Affiliations :
Eye Center of the Second Hospital of Jilin University, Changchun, Jilin, China.
Publications dans "Pigments rétiniens" :
2 publications dans cette catégorie
Affiliations :
Eye Center of the Second Hospital of Jilin University, Changchun, Jilin, China.
Publications dans "Pigments rétiniens" :
2 publications dans cette catégorie
Affiliations :
Eye Center of the Second Hospital of Jilin University, Changchun, Jilin, China.
Publications dans "Pigments rétiniens" :
2 publications dans cette catégorie
Affiliations :
Eye Center of the Second Hospital of Jilin University, Changchun, Jilin, China.
Publications dans "Pigments rétiniens" :
2 publications dans cette catégorie
Affiliations :
Eye Center of the Second Hospital of Jilin University, Changchun, Jilin, China.
Publications dans "Pigments rétiniens" :
Longevity is written into the genes. While many so-called "longevity genes" have been identified, the reason why particular genetic variants are associated with longer lifespan has proven to be elusiv...
Neovascular glaucoma (NVG) is a potentially blinding, secondary glaucoma. It is caused by the formation of abnormal new blood vessels, which prevent normal drainage of aqueous from the anterior segmen...
To assess the effectiveness of intraocular anti-VEGF medications, alone or with one or more types of conventional therapy, compared with no anti-VEGF medications for the treatment of NVG....
We searched CENTRAL (which contains the Cochrane Eyes and Vision Trials Register); MEDLINE; Embase; PubMed; and LILACS to 19 October 2021; metaRegister of Controlled Trials to 19 October 2021; and two...
We included randomized controlled trials (RCTs) of people treated with anti-VEGF medications for NVG....
Two review authors independently assessed the search results for trials, extracted data, and assessed risk of bias, and the certainty of the evidence. We resolved discrepancies through discussion....
We included five RCTs (356 eyes of 353 participants). Each trial was conducted in a different country: two in China, and one each in Brazil, Egypt, and Japan. All five RCTs included both men and women...
Anti-VEGFs as an adjunct to conventional treatment could help reduce IOP in NVG in the short term (four to six weeks), but there is no evidence that this is likely in the longer term. Currently availa...
Proliferative diabetic retinopathy (PDR) is an advanced complication of diabetic retinopathy that can cause blindness. It consists of the presence of new vessels in the retina and vitreous haemorrhage...
To assess the effectiveness and safety of anti-VEGFs for PDR and summarise any relevant economic evaluations of their use....
We searched CENTRAL (which contains the Cochrane Eyes and Vision Trials Register; 2022, Issue 6); Ovid MEDLINE; Ovid Embase; the ISRCTN registry; ClinicalTrials.gov, and the WHO ICTRP. We did not use ...
We included randomised controlled trials (RCTs) comparing anti-VEGFs to another active treatment, sham treatment, or no treatment for people with PDR. We also included studies that assessed the combin...
Two review authors independently selected studies for inclusion, extracted data, and assessed the risk of bias (RoB) for all included trials. We calculated the risk ratio (RR) or the mean difference (...
We included 15 new studies in this update, bringing the total to 23 RCTs with 1755 participants (2334 eyes). Forty-five per cent of participants were women and 55% were men, with a mean age of 56 year...
Anti-VEGFs ± PRP compared with PRP alone probably increase visual acuity, but the degree of improvement is not clinically meaningful. Regarding secondary outcomes, anti-VEGFs ± PRP produce a regressio...
The utilization of growth factors in the process of tissue regeneration has garnered significant interest and has been the subject of extensive research. However, despite the fervent efforts invested ...
Condylar hyperplasia (CH) is a rare condition characterised by excessive unilateral growth of the mandibular condyle after cessation of growth on the contralateral side causing facial asymmetry, being...
The aim of this study was to determine the utility of vascular endothelial growth factor (VEGF-A) as a diagnostic and prognostic factor in condylar hyperplasia, and to determine its potential viabilit...
This is a case-control study, where 17 mandibular condyles specimens were collected from 17 patients treated for active mandibular condyle hyperplasia and three unaffected human mandibular condyles fr...
VEGF-A was qualitatively found to be greatly upregulated in patients with condylar hyperplasia....
VEGF-A was qualitatively found to be upregulated in patients affected by CH, validating VEGF-A as a potential diagnostic, prognostic and therapeutic target....
COVID-19 is characterized by immunological responses to viral replication and coherent with endothelitis, microvascular disturbance of lung vasculature and coagulopathy. Vascular Endothelial Growth Fa...
After retrospective screening of all SARS-CoV-2-positive patients treated in Unfallkrankenhaus Berlin in 2020, we included those with documented VEGF measurement. We extracted laboratory values and cl...
We included 167 SARS-CoV-2-positive patients of which 139 suffered from COVID-19. Seventy-one of the COVID-19 patients had to be treated in the intensive care unit (ICU), those patients exhibited high...
Even though there are several limitations to this retrospective study it revealed that in COVID-19 patients VEGF can contribute to the prediction of necessity of ICU, mortality and the prediction of A...
Tissular hypoxia stimulates vascular morphogenesis. Vascular morphogenesis shapes the cell and, consecutively, tissue growth. The development of new blood vessels is intermediated substantially throug...
The vascular endothelial growth factor-A (VEGFA) system is a complex set of proteins, with multiple isoforms and receptors, including both angiogenic (VEGFxxx, VEGFR2) and antiangiogenic members (VEGF...
To investigate the relationship between angiotensin II (Ang II), vascular endothelial growth factor (VEGF), and arteriosclerosis obliterans (ASO)....
60 ASO patients diagnosed and treated from October 2019 to December 2021 were selected for the observation group while 30 healthy physical examiners were for the control group. The general information...
(1) The proportion of males with a history of smoking, diabetes, and hypertension was higher (...
Ang II and VEGF were correlated with the occurrence and development of ASO. The AUC analysis demonstrates that Ang II and VEGF were highly discriminative of ASO....
The objective of this study was to investigate the possible association between the single nucleotide polymorphism (SNP), rs35569394, of the vascular endothelial growth factor gene (VEGF) and the risk...